SAM
ADAP

Simplify Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Simplify Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,000
Closed -$117K – 116
2023
Q3 		$117K Hold
150,000
– – 0.01% 122
2023
Q2 		$139K Hold
150,000
– – 0.02% 112
2023
Q1 		$164K Buy
+150,000
New +$232K 0.02% 115

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Simplify Asset Management's ADAP Position: Q4 2023 in Review

Simplify Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 150,000 shares — an estimated $117K sold.

Simplify Asset Management first reported a position in ADAP in Q1 2023 and held it in 3 quarters. The position peaked at $164K in Q1 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • Simplify Asset Management reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Simplify Asset Management sold 150,000 Adaptimmune Therapeutics shares in Q4 2023, an estimated $117K.
  • Simplify Asset Management first reported a position in Adaptimmune Therapeutics in Q1 2023 and held it in 3 quarters.
  • Simplify Asset Management's Adaptimmune Therapeutics position peaked at $164K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Simplify Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.